Quick Listen: Scrip's Five Must-Know Things
Executive Summary
In this week's podcast edition of Five Must-Know Things: J&J and Roche’s first-half wins and challenges; Alexion’s Ultomiris plans; GSK’s AI and genomics investments; and a wide-ranging chat with the former secretary of the US department of Veterans Affairs.
Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by Scrip's global team, in this podcast version of Five Must-Know Things.
This episode covers insights for the business week ended 21 October 2022, including: Johnson & Johnson and Roche Holding AG’s first-half wins and challenges; Alexion Pharmaceuticals Inc.’s Ultomiris plans; GSK plc’s AI and genomics investments; and a wide-ranging chat with the former secretary of the US department of Veterans Affairs.
This and all our other podcasts are available on the Pharma Intelligence channel on Apple Podcasts, Google Podcasts, SoundCloud, TuneIn and Spotify Podcasts, and via smart speakers if one of these platforms has been set up as your default podcast provider.
Stories mentioned in this episode:
(Also see "With Stelara's Star Set To Fade, J&J Assures Investors It Will Grow Anyway" - Scrip, 18 Oct, 2022.)
(Also see "Vabysmo Is Bright Spot For Roche In Bumpy Q3" - Scrip, 18 Oct, 2022.)
(Also see "Alexion’s Ultomiris Expands Its Reach As Soliris Biosimilars Loom" - Scrip, 17 Oct, 2022.)
(Also see "GSK’s New Research Chief Begins Leadership With Expanded Genomics/AI Alliance" - Scrip, 18 Oct, 2022.)
(Also see "US Price Control, Outcomes-Based Contracting: Reflections Of Former VA Secretary Shulkin" - Scrip, 17 Oct, 2022.)